Close Menu

NEW YORK (GenomeWeb) – Cancer Genetics today priced its public offering of more than 13 million shares of its common stock at $.225 per share.

The company expects gross proceeds $3 million from the offering, which includes a 45-day option to its underwriter to purchase up to an additional 2 million shares of common stock at $.225 per share. The offering is expected to close on or about Jan. 14.

HC Wainwright is the sole book-running manager for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.